102 related articles for article (PubMed ID: 21824151)
1. Clastogenic plasma factors in psoriasis--comparison of phototherapy and anti-TNF-α treatments.
Emerit I; Antunes J; Silva JM; Freitas J; Pinheiro T; Filipe P
Photochem Photobiol; 2011; 87(6):1427-32. PubMed ID: 21824151
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
3. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.
Renzo LD; Saraceno R; Schipani C; Rizzo M; Bianchi A; Noce A; Esposito M; Tiberti S; Chimenti S; DE Lorenzo A
Dermatol Ther; 2011; 24(4):446-51. PubMed ID: 21910803
[TBL] [Abstract][Full Text] [Related]
4. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
Koc E; Tunca M; Akgul EO; Akar A; Kurt Y; Kurumlu Z; Erbil K; Kilic S
J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
[TBL] [Abstract][Full Text] [Related]
5. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.
Gambichler T; Tigges C; Scola N; Weber J; Skrygan M; Bechara FG; Altmeyer P; Kreuter A
Br J Dermatol; 2011 Jun; 164(6):1383-6. PubMed ID: 21466532
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
7. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
[TBL] [Abstract][Full Text] [Related]
8. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
9. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
10. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy of local narrowband ultraviolet B (NB-UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis.
Sezer E; Erbil AH; Kurumlu Z; Taştan HB; Etikan I
J Dermatol; 2007 Jul; 34(7):435-40. PubMed ID: 17584319
[TBL] [Abstract][Full Text] [Related]
12. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
Krueger G; Callis K
Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
Pomerantz RG; Mody E; Husni ME; Qureshi AA
J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis.
De Simone C; D'Agostino M; Capizzi R; Capponi A; Venier A; Caldarola G
Eur J Dermatol; 2011; 21(4):568-72. PubMed ID: 21697032
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
Kakkassery V; Mergler S; Pleyer U
Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052
[TBL] [Abstract][Full Text] [Related]
18. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept).
Cecchi R; Bartoli L
Dermatol Online J; 2006 Dec; 12(7):4. PubMed ID: 17459290
[TBL] [Abstract][Full Text] [Related]
20. CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy.
Yıldırım FE; Karaduman A; Pinar A; Aksoy Y
Int J Dermatol; 2011 Aug; 50(8):948-55. PubMed ID: 21781066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
